利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

94 条记录 (耗时 0.043 秒)

    Anti-IgE antibodies
    1.
    发明申请
    Anti-IgE antibodies 审中-公开
    抗IgE抗体

    公开(公告)号：US20080003218A1

    公开(公告)日：2008-01-03

    申请号：US11401765

    申请日：2006-04-11

    申请人： Henry Lowman ,  Leonard Presta ,  Paula Jardieu ,  John Lowe

    发明人： Henry Lowman ,  Leonard Presta ,  Paula Jardieu ,  John Lowe

    IPC分类号： A61K39/395 ,  A61P11/06 ,  A61P37/00 ,  C07K16/00 ,  C12N15/13 ,  C12N5/10 ,  C12P21/00

    CPC分类号： C07K16/4291 ,  A61K39/39566 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  A61K2300/00

    摘要： The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.

    摘要翻译： 本发明涉及通过以下步骤的组合来调节多肽与靶分子的亲和力的方法，包括：（1）鉴定易于异构化的天冬氨酰残基; （2）替代替代残基并筛选得到的突变体对靶分子的亲合力。 在优选的实施方案中，残基残基的方法是用噬菌体展示（AMPD）进行亲和力成熟。 在另一优选实施方案中，多肽是抗体，靶分子是抗原。 在另一个优选的实施方案中，抗体是抗IgE，靶分子是IgE。 在另一个实施方案中，本发明涉及对IgE具有改善的亲和力的抗IgE抗体。

    Method of Treatment Using Humanized Anti-CD11a Antibodies
    2.
    发明申请
    Method of Treatment Using Humanized Anti-CD11a Antibodies 审中-公开
    人源化抗CD11a抗体治疗方法

    公开(公告)号：US20070231328A1

    公开(公告)日：2007-10-04

    申请号：US11531667

    申请日：2006-09-13

    申请人： Paula Jardieu ,  Leonard Presta

    发明人： Paula Jardieu ,  Leonard Presta

    IPC分类号： A61K39/395

    CPC分类号： C07K16/2845 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2319/00

    摘要： Humanized anti-CD11a antibodies and various uses therefor are disclosed. The humanized anti-CD11a antibody may bind specifically to human CD11a I-domain, have an IC50(nM) value of no more than about 1 nM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1, and/or an IC50 (nM) value of no more than about 1 nM in the mixed lymphocyte response assay.

    摘要翻译： 公开了人源化抗CD11a抗体及其各种用途。 和/或表达ICA-1的人类抗CD11a抗体可以特异性结合人CD11a I-结构域，具有不大于约1nM的IC 50（nM）值以防止Jurkat细胞粘附到正常的人表皮角化细胞上，和/或 在混合淋巴细胞反应测定中IC50（nM）值不超过约1nM。

    NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
    9.
    发明申请
    NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION 审中-公开
    血管内皮生长因子活性的新型抑制剂，其生产用途及其制备方法

    公开(公告)号：US20070128695A1

    公开(公告)日：2007-06-07

    申请号：US11537623

    申请日：2006-09-30

    申请人： Terri Davis-Smyth ,  Helen Chen ,  Leonard Presta ,  Napoleone Ferrara

    发明人： Terri Davis-Smyth ,  Helen Chen ,  Leonard Presta ,  Napoleone Ferrara

    IPC分类号： C07K14/71 ,  C07K16/28 ,  C07H21/04 ,  C12P21/06

    CPC分类号： C07K14/71 ,  A61K38/00 ,  C07K16/2863 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31

    摘要： The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.

    摘要翻译： 本发明涉及包含衍生自血管内皮生长因子（VEGF）受体flt-1和KDR的氨基酸序列的新型嵌合VEGF受体蛋白，包括人KDR受体FLK-1的鼠同源物，其中所述嵌合VEGF受体 蛋白质结合VEGF并拮抗其内皮细胞增殖和血管生成活性。 本发明还涉及编码这些嵌合VEGF受体蛋白质的核酸和表达载体，含有这种表达载体的宿主细胞，包含这种蛋白质的药学上可接受的组合物，制备这种蛋白质的方法以及利用这些蛋白质治疗相关病症的方法 具有不希望的血管形成。